This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strategic Partnerships Power Tempus AI's Healthcare Expansion
by Sridatri Sarkar
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
by Urmimala Biswas
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Urmimala Biswas
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?
by Urmimala Biswas
TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
by Urmimala Biswas
Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
by Urmimala Biswas
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of -23.81% and 7.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?
by Urmimala Biswas
The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
by Urmimala Biswas
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 4.17% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
by Urmimala Biswas
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 6.52% and 0.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI Stock Before Q4 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the fourth quarter, banking on continued unit growth pick-up.
The Zacks Analyst Blog Highlights Tempus AI, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, iRhythm Technologies and SOPHiA GENETICS are part of the Zacks top Analyst Blog.
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
by Urmimala Biswas
TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.
Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Standard BioTools (LAB) delivered earnings and revenue surprises of 37.50% and 7.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
by Zacks Equity Research
SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 17.86% and 10.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?